NDAINTRAVENOUSEMULSION
Approved
Aug 2008
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
6/8 — Strong
CLEVIPREX (clevidipine) by Chiesi is calcium channel antagonists [moa]. Approved for dihydropyridine calcium channel blocker [epc]. First approved in 2008.
Drug data last refreshed 3d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLEVIPREX (clevidipine) is an intravenous dihydropyridine calcium channel blocker approved in 2008 for acute hypertension and perioperative blood pressure management. It works by blocking calcium influx into vascular smooth muscle, causing rapid vasodilation and blood pressure reduction in acute care settings.
Peak5.4 years to LOE
CLEVIPREX is in peak commercial stage with stable perioperative adoption, though modest team size expected given niche IV-only indication and limited public spending data.
Mechanism of Action
Calcium Channel Antagonists
Pharmacologic Class:
Dihydropyridine Calcium Channel Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
Started Jun 2024
1,000 enrolled
Intracerebral HemorrhageStrokeHypertension
a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency
Started Jul 2023
378 enrolled
Hypertensive Emergency
Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER)
Started Mar 2014
22 enrolled
Pediatric Perioperative Blood Pressure Management
Career Relevance
CLEVIPREX offers career opportunity in a niche but stable perioperative franchise with highly specialized clinical users (anesthesiologists, intensivists, OR nurses) requiring focused medical and sales expertise. The approaching patent cliff (5.5 years) creates urgency for market share consolidation and long-term strategy work, making this suitable for mid-career professionals seeking focused therapeutic expertise.
Worked on CLEVIPREX at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.